In the rapidly evolving landscape of post-pandemic corporate governance, the compensation strategies for key executives have become a focal point for many firms. As evidenced by recent data, Moderna Inc., a biotechnology and pharmaceutical leader, has significantly increased the total compensation for its chief legal officer, Shannon Thyme Klinger. According to Moderna’s proxy filing, Klinger’s compensation soared to approximately $17.4 million in 2024.
This figure represents a substantial increase from her previous earnings of $4.3 million in 2023 and $3.7 million in 2022. The marked rise in her compensation is largely attributed to about $15.8 million in stock and option awards, a strategic move by Moderna to ensure retention and incentivize key leadership during this transitional phase.
Shannon Klinger, who joined Moderna from Novartis AG in 2021, played a pivotal role in steering the company through complex litigation and regulatory challenges. Notably, the approach of using equity awards highlights a broader trend among corporations seeking to align executive performance with long-term shareholder value. While Moderna and Klinger have not responded to requests for additional comments, the compensation adjustment underscores the company’s strategic planning to bolster its executive team amid a significant post-pandemic business realignment. For further reading on this development, Bloomberg Law provides a detailed overview here.